Loading
A phase 2 trial of cAPOX (capecitabine, oxaliplatin), capecitabine and cadonilimab in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC is a phase 2, interventional study registered as NCT06405490 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 30 participants, started 2024-04-17 and due to reach its primary completion in 2026-08-30. Interventions recorded: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab. Conditions listed: Nanoliposomal Irinotecan; Cadonilimab; Oxaliplatin; Capecitabine; First-Line; Advanced Cancer; Pancreatic Adenocarcinoma; Drug Use. Primary outcome: Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares CAPOX (capecitabine, oxaliplatin), Pancreatic cancer trials open today (registry snapshot and UK sites), Capecitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/